



# **DISA Limited**

## **Business Updates**

25 October 2024

## Areas of Focus – Eye Screening Devices

---

- Marketing of automated visual acuity test (“**AVAT**”) device into ASEAN countries
- Development of new device known as mobile eye-imaging device (“**MIDAS**”) for detecting eye pathologies
- Product registration outside Singapore

# Increasing Demand for Vision Screening Market

According to PharmiWeb.com, the global vision screeners market is anticipated to exceed **US\$815.2 million** by 2029<sup>1</sup>.

Population growth, digital eye strain, rising prevalence of diabetes, and ageing are expected to increase the risk that more people acquire vision impairment, highlighting the urgent need for early screening to slow down vision loss and blindness.

## 180,000

**Singapore** - Approximate number of adults aged above 60 who have visual impairment. This number is expected to **double** by 2030<sup>2</sup>.

## 2.2 billion

**Global** - Approximate number of people who have vision impairment, with at least 1 billion (50%) in which vision impairment could have been prevented with early detection. This is estimated to cost the global economy over US\$3 trillion every year in lost productivity and health and social care<sup>3</sup>.

<sup>1</sup> <https://www.pharmiweb.com/press-release/2023-07-03/vision-screeners-market-is-anticipated-to-reach-us-8152-million-by-2029-with-a-cagr-of-59>

<sup>2</sup> <https://www.singhealth.com.sg/news/research/new-study-investigate-vision-hearing-loss-development-dementia-singaporeans#:~:text=About%20180%2C000%20adults%20aged%2060%20years%20and%20above,by%202030%20with%20the%20country%E2%80%99s%20rapidly%20ageing%20population.>

<sup>3</sup> <https://www.iapb.org/wp-content/uploads/2020/09/WRV-IAPB-Summary.pdf>

# Visual Acuity Screening - AVAT

## Existing Infrastructure

Current vision screening devices are costly, require large spaces for use, and need to be supervised by trained staff, which limits testing productivity and creates long wait-times.



Screening equipment is bulky and expensive  
→ costly to expand vision testing to more sites



Manual vision screening  
→ more manpower is needed to support greater demand for tests




Visual acuity test requires space  
→ limits testing output in small clinic space




Long Wait-Times Create Bottleneck in Clinical Workflow

Worsening Manpower Shortage and High Turnover



## AVAT

Automated, accurate **visual acuity** testing that can be self-administered by patients with minimal or no supervision



- measures eyes' ability to distinguish shapes at a distance
- check ability to see near objects and distinguish between different colors

## Cataract Screening - MIDAS

---



- Smartphone-based lightweight, portable slit lamp compatible with most models
- Designed to be used with minimal training by GPs, nurses in primary care settings
- User-intuitive: fixed slit beam angle and intensity
- Augmented with AI model for autonomous cataract grading
- Objective cataract screening modality that can be used in the community to detect cataract cases for targeted treatment

# Stage of Business Development

	AVAT	MIDAS
	Visual Acuity Test	Cataract Screening
Product development	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Clinical validation	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
License	<input checked="" type="checkbox"/>	Q4 2024
Class A product registration		
- Singapore	<input checked="" type="checkbox"/>	Q4 2024
- Vietnam	<input checked="" type="checkbox"/>	Q1 2025
- Malaysia	<input checked="" type="checkbox"/>	Q1 2025
Class B product registration	N/A	Q1 2026
CE mark registration	Q1 2025	Q1 2026
Food and Drug Administration 510K registration	Q1 2026	Q2 2026
First commercial deployment	Q4 2024	Q3 2025 (as Class A only)

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in DISA Limited (“DISA”) in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any investment decision, contract or commitment whatsoever in this or any jurisdiction. This presentation may contain forward-looking statements that involve assumptions, risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. You are cautioned not to place undue reliance on these forward-looking statements, if any, which are based on the current view of management on future events. The information contained in this presentation has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Neither DISA or any of its affiliates, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

This presentation have been reviewed by the Company’s Sponsor, SAC Capital Private Limited (“Sponsor”).

This presentation has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this presentation including the correctness of any of the statements or opinions made or reports contained in this presentation.

The contact person for the Sponsor is Ms. Lee Khai Yinn (Registered Professional, SAC Capital Private Limited).  
Address: 1 Robinson Road #21-00 AIA Tower, Singapore 048542. Telephone number: +65 6232 3210